• linkedin
  • Increase Font
  • Sharebar

    9 Newly Approved Novel Drugs

    It's been a busy year for the FDA.

     

    Breast Cancer ribbon

    6. KISQALI (ribociclib), Novartis

    Indications: A kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

    Dosage: 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment.

    Contraindications: None

    Read the FDA statement here

    Read the full prescribing information here

    Previous ButtonNext Button

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available